These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 14707047)

  • 21. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
    He T; Tang C; Xu S; Moyana T; Xiang J
    Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.
    Yang SC; Hillinger S; Riedl K; Zhang L; Zhu L; Huang M; Atianzar K; Kuo BY; Gardner B; Batra RK; Strieter RM; Dubinett SM; Sharma S
    Clin Cancer Res; 2004 Apr; 10(8):2891-901. PubMed ID: 15102698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.
    Zhang W; He L; Yuan Z; Xie Z; Wang J; Hamada H; Cao X
    Hum Gene Ther; 1999 May; 10(7):1151-61. PubMed ID: 10340547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
    Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
    J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo.
    Sharma S; Stolina M; Luo J; Strieter RM; Burdick M; Zhu LX; Batra RK; Dubinett SM
    J Immunol; 2000 May; 164(9):4558-63. PubMed ID: 10779757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy.
    van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG
    Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo.
    Nitcheu-Tefit J; Dai MS; Critchley-Thorne RJ; Ramirez-Jimenez F; Xu M; Conchon S; Ferry N; Stauss HJ; Vassaux G
    J Immunol; 2007 Aug; 179(3):1532-41. PubMed ID: 17641019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutrophil-dependent tumor rejection and priming of tumoricidal CD8+ T cell response induced by dendritic cells overexpressing CD95L.
    Buonocore S; Haddou NO; Moore F; Florquin S; Paulart F; Heirman C; Thielemans K; Goldman M; Flamand V
    J Leukoc Biol; 2008 Sep; 84(3):713-20. PubMed ID: 18567840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.
    Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K
    J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
    Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
    Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL.
    Luketic L; Delanghe J; Sobol PT; Yang P; Frotten E; Mossman KL; Gauldie J; Bramson J; Wan Y
    J Immunol; 2007 Oct; 179(8):5024-32. PubMed ID: 17911587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Freezing and thawing of bone marrow-derived murine dendritic cells with subsequent retention of immunophenotype and of antigen processing and presentation characteristics.
    Sai T; Milling SW; Mintz B
    J Immunol Methods; 2002 Jun; 264(1-2):153-62. PubMed ID: 12191518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells.
    Means TK; Hayashi F; Smith KD; Aderem A; Luster AD
    J Immunol; 2003 May; 170(10):5165-75. PubMed ID: 12734364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
    Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity.
    He Y; Zhang J; Mi Z; Robbins P; Falo LD
    J Immunol; 2005 Mar; 174(6):3808-17. PubMed ID: 15749922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral tolerance to a nuclear autoantigen: dendritic cells expressing a nuclear autoantigen lead to persistent anergic state of CD4+ autoreactive T cells after proliferation.
    Kawahata K; Misaki Y; Yamauchi M; Tsunekawa S; Setoguchi K; Miyazaki J; Yamamoto K
    J Immunol; 2002 Feb; 168(3):1103-12. PubMed ID: 11801644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor immune response of dendritic cells (DCs) expressing tumor-associated antigens derived from induced pluripotent stem cells: in comparison to bone marrow-derived DCs.
    Iwamoto H; Ojima T; Hayata K; Katsuda M; Miyazawa M; Iida T; Nakamura M; Nakamori M; Iwahashi M; Yamaue H
    Int J Cancer; 2014 Jan; 134(2):332-41. PubMed ID: 23824921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes.
    Tanaka F; Yamaguchi H; Haraguchi N; Mashino K; Ohta M; Inoue H; Mori M
    Int J Oncol; 2006 Nov; 29(5):1263-8. PubMed ID: 17016660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.